Trident Texofab promoter trust buys 0.26% stake in open market

1 min read     Updated on 20 Aug 2026, 03:56 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Hardik Desai Family Trust increased its stake in Trident Texofab Ltd by acquiring 39,425 shares (0.26%) in the open market on August 17, 2026. The promoter group entity now holds 10,18,691 shares, amounting to a 6.79% stake in the company. The disclosure was made to BSE under SEBI takeover regulations, with no encumbrances reported on the shares.

powered bylight_fuzz_icon
48767169

*this image is generated using AI for illustrative purposes only.

The Hardik Desai Family Trust, identified as part of the promoter group of Trident Texofab , acquired an additional stake in the textile manufacturer through the open market. The trust purchased 39,425 equity shares on August 17, 2026, representing a 0.26% increase in its voting power relative to the total share capital.

Following this acquisition, the trust’s total holding stands at 10,18,691 shares, which accounts for 6.79% of the company’s total voting capital. Prior to this transaction, the entity held 9,79,266 shares, constituting a 6.53% stake. The disclosure was filed with BSE Limited on August 20, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Structure

The acquisition was conducted entirely through the open market mechanism. The disclosure indicates no changes to the company’s total equity share capital, which remains at Rs. 14,99,57,640 (1,49,95,764 equity shares of Rs. 10 each). There were no warrants, convertible securities, or other instruments entitling the acquirer to receive shares carrying voting rights involved in this transaction.

Metric Before Acquisition Change After Acquisition
Shares held 9,79,266 +39,425 10,18,691
Stake percentage 6.53% +0.26% 6.79%
Encumbered shares - - -

Regulatory Compliance

The filing was submitted by Hardik Jigishkumar Desai, acting as trustee for the Hardik Desai Family Trust. The document confirms that the acquirer belongs to the promoter category and lists Trident Texofab Limited as the target company. The trust’s address is recorded as Seema Row House, Opp Krushi Farm, Ghod Dod Road, Umra, Surat.

No shares were reported as encumbered with pledge, lien, or non-disposal undertakings either before or after the acquisition. The total diluted share/voting capital of Trident Texofab remains unchanged at Rs. 14,99,57,640 post-transaction.

Historical Stock Returns for Trident Texofab

1 Day5 Days1 Month6 Months1 Year5 Years
-4.99%+1.47%-34.31%-78.33%-89.86%-40.30%

Does this incremental open-market purchase signal the promoter group's confidence in Trident Texofab's upcoming financial performance or strategic initiatives?

How might this consolidation of promoter holding impact market sentiment and liquidity for retail investors in the near term?

Are there indications that the Hardik Desai Family Trust plans to cross the 7.5% or 10% disclosure thresholds, potentially triggering further regulatory filings?

Trident Texofab Q1 Results: Net profit turns positive at ₹52 lakh

1 min read     Updated on 12 Aug 2026, 06:41 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Trident Texofab Limited reported a net profit of ₹52.18 lakh for Q1FY26, reversing a ₹200.94 lakh loss from the previous quarter. Revenue declined to ₹2,632.79 lakh, down from ₹3,410.25 lakh in Q4FY25. The Board approved the results on August 10, 2026, under SEBI LODR regulations.

powered bylight_fuzz_icon
48085906

*this image is generated using AI for illustrative purposes only.

Trident Texofab Limited returned to profitability in the first quarter of FY26, reporting a net profit after tax of ₹52.18 lakh for the period ended June 30, 2026. This result marks a sharp reversal from the net loss of ₹200.94 lakh posted in the previous quarter (Q4FY25), signaling an operational improvement despite a decline in revenue. The company’s total income from operations fell to ₹2,632.79 lakh in Q1FY26, compared to ₹3,410.25 lakh in the prior quarter and ₹2,851.58 lakh in the same quarter last year.

The Board of Directors approved the unaudited standalone financial results on August 10, 2026, following a review by the Audit Committee. The results were filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed these figures via newspaper advertisements in Financial Express (English and Gujarati editions) on August 12, 2026, in compliance with Regulation 30 and Regulation 47 of the SEBI Listing Regulations.

Financial Performance Highlights

Metric Q1FY26 (₹ Lakh) Q4FY25 (₹ Lakh) Q1FY25 (₹ Lakh)
Total Income from Operations 2,632.79 3,410.25 2,851.58
Net Profit Before Tax 68.72 -130.75 136.92
Net Profit After Tax 52.18 -200.94 101.59
Basic EPS (₹) 0.35 -1.30 0.72

The company generated a pre-tax profit of ₹68.72 lakh in the current quarter, up from a pre-tax loss of ₹130.75 lakh in Q4FY25. Earnings per share stood at ₹0.35 for both basic and diluted calculations, a notable improvement from the negative EPS of ₹-1.30 in the preceding quarter. Equity share capital remained unchanged at ₹1,499.58 lakh.

What the Numbers Show

The divergence between declining revenue and rising profitability suggests cost optimization or margin expansion drove the turnaround. While total income dropped by approximately 23% quarter-on-quarter, the company managed to swing from a significant loss to a profit position. This indicates that fixed costs may have been better absorbed or variable costs reduced relative to sales volume, although specific operational drivers were not detailed in the filing. The year-over-year comparison shows lower profits than Q1FY25 (₹101.59 lakh), highlighting that while the immediate trend is positive, it has not yet returned to the levels seen in the corresponding period of the previous fiscal year.

Historical Stock Returns for Trident Texofab

1 Day5 Days1 Month6 Months1 Year5 Years
-4.99%+1.47%-34.31%-78.33%-89.86%-40.30%

What specific cost-cutting measures or operational efficiencies enabled Trident Texofab to achieve profitability despite a 23% quarter-on-quarter decline in revenue?

Can management provide guidance on whether the current margin expansion is sustainable as the company attempts to rebuild its revenue base in Q2FY26?

How does the company plan to address the significant year-over-year profit gap, given that Q1FY26 net profit is roughly half of Q1FY25 levels?

More News on Trident Texofab

1 Year Returns:-89.86%